Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Stroke, Acute
Interventions: Nerinetide (NA-1), 2.6 mg/kg, Placebo; Drug
Lead sponsor: NoNO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 20
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 17 more

Conditions: Advanced Illness Patients With Opioid Induced Constipation
Interventions: SC Methylnaltrexone, SC Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Healthy
Interventions: QAX576; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Acute Kidney Injury
Interventions: Suramin, Placebo; Drug
Lead sponsor: Rediscovery Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Little Rock, Arkansas • La Mesa, California • Los Angeles, California + 9 more

Conditions: Spasticity
Interventions: Corabotase, Placebo, Dysport; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions: ETX2514, Placebo, moxifloxacin; Drug
Lead sponsor: Entasis Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stable Atherothrombotic Disease
Interventions: CSL112 (reconstituted high density lipoprotein), Placebo; Biological
Lead sponsor: CSL Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Chula Vista, California • Jacksonville, Florida • Miami, Florida + 8 more

Conditions: Tuberculosis
Interventions: TBA-354, Placebo; Drug · Other
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Acute Decompensated Heart Failure
Interventions: CD-NP; Drug
Lead sponsor: Nile Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Los Angeles, California • Torrance, California • Jacksonville, Florida + 7 more

Conditions: Digestive System Disease
Interventions: Low-dose PvP001, Medium-dose PvP001, High-dose PvP001, Placebo; Drug
Lead sponsor: Danielle Kim Turgeon; Other
Eligibility: 18 Years to 64 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine; Drug · Biological
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions: ATTO-3712, Placebo; Drug
Lead sponsor: Attovia Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more

Conditions: Asthma in Children, Atopy, Viral Upper Respiratory Infection
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: HEC 68498, Placebo; Drug
Lead sponsor: Sunshine Lake Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Subjects
Interventions: AV650; Drug
Lead sponsor: Avigen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine
Interventions: AMG 333, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Morning Sickness
Interventions: Bonjesta, Placebo; Drug
Lead sponsor: Duchesnay Inc.; Industry
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 274 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Burbank, California • Hialeah, Florida • Miami, Florida + 7 more

Conditions: Psoriasis
Interventions: Placebo, SRT2104; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: St Louis, Missouri • New York, New York • Portland, Oregon + 4 more

Conditions: Pleural Effusion
Interventions: LTI-01, Placebo; Drug
Lead sponsor: Rein Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 27 more

Conditions: Attention Deficit-Hyperactivity
Interventions: MYDAYIS, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: MN-221, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: Loma Linda, California • San Diego, California • Sylmar, California + 11 more

Conditions: Healthy Volunteers
Interventions: AZD8108, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Adult Attention-Deficit Hyperactivity Disorder
Interventions: Guanfacine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Search by objective public record fields.

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.

Study of Suramin in Subjects With Furosemide-Resistant AKI

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

Gastric Gluten-Degradation Activity of PvP001

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

Omalizumab Before Onset of Exacerbations

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

AZD8108 SAD/MAD in Healthy Volunteers

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).